Clinical, kinematic and electrophysiological characterisation of patients with multiple systems atrophy and pharmacological modulation by venlafaxin.
- Conditions
- G23.2Multiple system atrophy, parkinsonian type [MSA-P]
- Registration Number
- DRKS00034001
- Lead Sponsor
- niversitätsklinikum Hamburg-Eppendorf
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
age > 30 years
- sporadic onset and gradual progression
- clinical diagnosis of probable or possible MSA-P according to MDS-criteria
Exclusion Criteria
- severe impairment of vision
- no ability to give informed consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in neuropsychiatric/cognitive symptoms assessed by Trail Making Test (TMT), Starkstein Apathy Scale (SAS), and Geratric Depression Scale (GDS) after treatment with Venlafaxin for at least 4 weeks compared to scores before treatment.
- Secondary Outcome Measures
Name Time Method Changes in parameters of gait analysis, pupillometry and EEG as well as changes in clinical scores in the Unified MSA Rating Scale (UMSARS), the Montreal Cognitive Assessment (MoCA-Test), the Three-clap Test, Luria-sequence, verbal fluency, Frontal Assessment Battery (FAB), Schwab and England Activities of Daily Living (SEADL), MSA-Qualtity of Life Scale (MSA-QoL) and Munich Dysphagia Test (MDT).<br>All parameters are assessed before and after Venlafaxin intervention.